<?xml version="1.0" encoding="UTF-8"?>
<p>Clinical trials of oral PrEP (pre-exposure prophylaxis) for HIV-negative individuals conducted in Thailand showed a reduction in HIV acquisition in MSM
 <xref rid="ref13" ref-type="bibr">13</xref>, and in PWID
 <xref rid="ref14" ref-type="bibr">14</xref>. The US FDA (Food and Drug Administration) approved daily oral Truvada for PrEP in 2012 and WHO and CDC recommended PrEP for certain populations. The PROUD and on-demand ‘Ipergay’ PrEP studies showed a relative reduction of 86 per cent in HIV incidence among MSM
 <xref rid="ref15" ref-type="bibr">15</xref>
 <xref rid="ref16" ref-type="bibr">16</xref>. Long-acting injectable PrEP may have the preference of target populations and circumvent the issue of adherence but the supply of the drug would need to match the increasing demand to ensure success of this new biomedical prevention modality. Key for optimum coverage, PrEP costs should be covered by the national health programmes where PrEP is now recommended.
</p>
